By Stephen Nakrosis

AbbVie Inc. on Monday said it was submitting applications to the U.S. Food and Drug Administration and the European Medicines Agency for its Rinvoq to treat patients with active psoriatic arthritis.

Psoriatic arthritis is an inflammatory condition that affects people suffering from psoriasis.

The company said it based its submissions on "two Phase 3 studies in which Rinvoq demonstrated improved joint outcomes, physical function and skin symptoms, with a greater proportion of patients achieving minimal disease activity versus placebo."

The company said Rinvoq, or upadacitinib, was "discovered and developed by AbbVie scientists" and is a "selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases." 



  --Write to Stephen Nakrosis at stephen.nakrosis@wsj.com